Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
MNPR · Why this verdict
Why Monopar Therapeutics (MNPR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
MNPR carries a fresh positive analyst-news signal and strong momentum, but quality sits well below the engine's floor with cash burn, margin compression, high leverage, and an already-reached price target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock trips two of five value-trap signals: severe margin compression, with an operating margin of -140.3%, and high leverage at a 4.1 debt-to-equity ratio. Bear case | Operating margin should improve toward breakeven and leverage should decline, dropping the value-trap signal count below 2 of 5. | ↑Improving |
| CounterThe peer ranking notes conservative debt levels relative to peers, suggesting the leverage figure may be less concerning in a sector context. | ||
Quality is scored 1.6, well below the engine's 4.0 floor, driven by negative free cash flow and the absence of a competitive moat. Quality breakdown | Free cash flow should turn positive and the quality score should climb toward the 4.0 floor as cash burn slows. | →Stable |
| CounterClinical-stage biotechs routinely burn cash pre-commercialization, so a low quality score here may reflect business-model stage rather than execution risk. | ||
The stock has essentially reached its analyst target with only 1.1% modeled upside, and the V9 asymmetry gate failed at a 0.07 ratio against the 1.5 threshold. Engine gate (failed) | The asymmetry ratio should rise above 1.5 as a higher analyst target is issued or price consolidates. | →Stable |
| CounterA recent analyst news detection generated a positive 0.70 sentiment boost, which could precede an upward target revision. | ||
Momentum is strong but the stock is extremely overbought with an RSI of 93, alongside rising on-balance volume and a position above the 200-day moving average. Momentum breakdown | RSI should cool from 93 toward a more sustainable 50-70 range without a sharp price reversal. | ↓Deteriorating |
| CounterThe recent positive analyst-news sentiment could sustain buying pressure even at an extreme RSI reading. | ||
Short interest is elevated at 34% of float, which the engine explicitly flags as justified given the stock's underlying risk profile. Risk breakdown | Short interest should decline from 34% as quality concerns are resolved or the thesis plays out. | ↑Improving |
| CounterExtremely high short interest combined with rising OBV volume accumulation can set up a short-covering squeeze rather than confirm further downside. | ||
The stock trips two of five value-trap signals: severe margin compression, with an operating margin of -140.3%, and high leverage at a 4.1 debt-to-equity ratio.
↑ImprovingBear case
- Expectation
- Operating margin should improve toward breakeven and leverage should decline, dropping the value-trap signal count below 2 of 5.
CounterThe peer ranking notes conservative debt levels relative to peers, suggesting the leverage figure may be less concerning in a sector context.
Quality is scored 1.6, well below the engine's 4.0 floor, driven by negative free cash flow and the absence of a competitive moat.
→StableQuality breakdown
- Expectation
- Free cash flow should turn positive and the quality score should climb toward the 4.0 floor as cash burn slows.
CounterClinical-stage biotechs routinely burn cash pre-commercialization, so a low quality score here may reflect business-model stage rather than execution risk.
The stock has essentially reached its analyst target with only 1.1% modeled upside, and the V9 asymmetry gate failed at a 0.07 ratio against the 1.5 threshold.
→StableEngine gate (failed)
- Expectation
- The asymmetry ratio should rise above 1.5 as a higher analyst target is issued or price consolidates.
CounterA recent analyst news detection generated a positive 0.70 sentiment boost, which could precede an upward target revision.
Momentum is strong but the stock is extremely overbought with an RSI of 93, alongside rising on-balance volume and a position above the 200-day moving average.
↓DeterioratingMomentum breakdown
- Expectation
- RSI should cool from 93 toward a more sustainable 50-70 range without a sharp price reversal.
CounterThe recent positive analyst-news sentiment could sustain buying pressure even at an extreme RSI reading.
Short interest is elevated at 34% of float, which the engine explicitly flags as justified given the stock's underlying risk profile.
↑ImprovingRisk breakdown
- Expectation
- Short interest should decline from 34% as quality concerns are resolved or the thesis plays out.
CounterExtremely high short interest combined with rising OBV volume accumulation can set up a short-covering squeeze rather than confirm further downside.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.1 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.8 |
| Analyst rating | 5.0 |
| Price target | 6.8 |
- ▸LLM news sentiment: +0.55 (n=2)
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 7.3 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.3 |
| support resistance | 4.2 |
| 52w position | 7.8 |
| gap | 6.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.2 |
| days to cover | 0.0 |
| volatility | 0.0 |
| beta | 5.1 |
| debt equity | 10.0 |
| news risk | 6.0 |
- ▸High short interest justified: 33%
Catalyst
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 7.1 |
| news activity | 6.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.50
- EARNINGS_PROXIMITY:21d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.3<4.5
- ASYMMETRY:-0.1=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.12
Upside
-1.8%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 55 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.3<4.5 outcome against Insider at 7.3 and asymmetric R:R of -0.12.
The strongest dimensions are Insider at 7.3, Peer rank at 6.7, and Sentiment at 6.5; the weakest are Quality at 1.6, Momentum at 3.3, and Risk (lower is worse) at 3.6. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of -0.12 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Floor Cash Burning
Trip ifQuality score rises above 4.0, clearing the engine's quality floor as free cash flow turns positive.
- P2Analyst Target Reached Negative Asymmetry
Trip ifAsymmetry ratio exceeds 1.5, clearing the V9 gate that currently fails at 0.07.
- P3Value Trap Margin Compression And Leverage
Trip ifOperating margin rises above -20% and debt-to-equity falls below 2.0, clearing two value-trap signals.
- P4Overbought Momentum Condition
Trip ifRSI falls below 50 alongside a price decline of more than 10% from the current level.
- P5Justified High Short Interest
Trip ifShort interest falls below 15% of float, well off the current 34% reading.